Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

H. Carlo Maurer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2193-6014; OpenAlex author ID A5032644187, A5148323810. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
143
Papers, trials and grants by year

2018: 2 papers · 2019: 6 papers · 2020: 3 papers · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 4 papers

Papers 28

  1. Regulatory elements in the Sox9 locus license the initiation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117176↗
  2. Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer. Co-author DOI 10.1038/s41588-026-02714-8↗
  3. PHGDH is a targetable driver of PDAC progression Co-author DOI 10.64898/2026.03.11.711147↗
  4. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Co-author DOI 10.64898/2026.06.26.734719↗
  5. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  6. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  7. Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression. Co-author DOI 10.1158/2159-8290.cd-23-0240↗
  8. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer Co-author DOI 10.1101/2023.03.19.533333↗
  9. Bone Morphogenetic Protein (BMP) signaling upregulates expression of ID1 and ID3 in pancreatitis and pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.09.01.555987↗
  10. Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.12.24.573257↗
  11. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. Co-author DOI 10.1172/jci.insight.154475↗
  12. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  13. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  14. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  15. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. First author DOI 10.1053/j.gastro.2020.09.010↗
  16. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  17. Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic… Co-author DOI 10.3390/cancers13071535↗
  18. HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. Co-author DOI 10.1016/j.yexcr.2020.111960↗
  19. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1101/gr.257550.119↗
  20. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1359↗
  21. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition. Co-author DOI 10.1016/j.trsl.2018.12.008↗
  22. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-12657-w↗
  23. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Co-author DOI 10.1038/s41467-019-13151-z↗
  24. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2017-314353↗
  25. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Co-author DOI 10.1136/gutjnl-2018-317706↗
  26. Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-18-3281↗
  27. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  28. Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma First author DOI 10.1101/288779↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenneth P. Olive · 20 shared papers, 2018–2026 · strength 2.40
  2. Roland Michael Schmid · 7 shared papers, 2021–2026 · strength 1.03
  3. Maximilian Reichert · 7 shared papers, 2018–2026 · strength 0.96
  4. Alina Cornelia Iuga · 6 shared papers, 2018–2026 · strength 0.70
  5. Andrea Califano · 5 shared papers, 2018–2026 · strength 0.65
  6. Roland Rad · 4 shared papers, 2021–2026 · strength 0.59
  7. Günter Schneider · 4 shared papers, 2021–2026 · strength 0.59
  8. Dieter Saur · 4 shared papers, 2021–2026 · strength 0.59
  9. Wilko Weichert · 4 shared papers, 2021–2025 · strength 0.52
  10. Álvaro Curiel‐García · 3 shared papers, 2023–2026 · strength 0.50
  11. Gulam Abbas Manji · 3 shared papers, 2023–2026 · strength 0.50
  12. Felix Orben · 3 shared papers, 2022–2025 · strength 0.49
  13. İhsan Ekin Demir · 3 shared papers, 2022–2025 · strength 0.49
  14. Pasquale Laise · 3 shared papers, 2019–2026 · strength 0.42
  15. Stefanie Bärthel · 2 shared papers, 2025–2026 · strength 0.38
  16. Daniele Lucarelli · 2 shared papers, 2025–2026 · strength 0.38
  17. Helmut Friess · 3 shared papers, 2021–2025 · strength 0.38
  18. Urszula N. Wasko · 2 shared papers, 2024–2026 · strength 0.38
  19. Elisa Espinet · 2 shared papers, 2022–2026 · strength 0.35
  20. Anna Melissa Schlitter · 2 shared papers, 2022–2026 · strength 0.33
  21. Luís Arnes · 2 shared papers, 2019–2026 · strength 0.32
  22. Gina M. DeNicola · 1 shared paper, 2026 · strength 0.32
  23. Yumi Kim · 1 shared paper, 2026 · strength 0.32
  24. Raphela A. Ranjan · 2 shared papers, 2021–2026 · strength 0.31
  25. Jeanine M. Genkinger · 3 shared papers, 2018–2023 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.